Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.
Related
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
